GMT Science provides a CE‑marked diagnostic platform that delivers quantitative metagenomic sequencing of the gut microbiome, processed through proprietary AI algorithms to produce reproducible, clinically actionable biomarkers. The service integrates with accredited labs and hospitals, enabling physicians to assess disease risk, monitor treatment response, and inform prognosis across oncology, hepatology, gastroenterology, endocrinology, and psychiatry.
Funding
Funding not disclosed
Founders
Product
Problem
Clinicians lack reliable, standardized tools to assess patients' gut microbiome for disease prevention, monitoring, and prognosis, despite growing evidence linking microbiota composition to conditions such as cancer, liver disease, bowel disorders, diabetes, obesity, and mental health.
Solution
GMT Science delivers clinical‑grade gut microbiome analysis through a CE‑marked diagnostic software platform. The service uses standardized quantitative metagenomic sequencing combined with proprietary AI algorithms to generate reproducible, high‑resolution microbiome profiles. Results are provided as actionable biomarkers that physicians can integrate into routine care for disease risk assessment, treatment monitoring, and prognostic evaluation. The platform is offered via accredited medical laboratories and hospitals, enabling seamless incorporation of microbiome insights into existing clinical workflows.
Target Audience
Primary customers are physicians and clinical laboratories seeking to incorporate microbiome diagnostics into the management of chronic diseases such as oncology, hepatology, gastroenterology, endocrinology, and psychiatry.
Features
- Standardized sample processing and quantitative metagenomic sequencing for consistent, high‑quality data
- Proprietary AI‑driven algorithms that translate raw metagenomic reads into clinically relevant microbiome biomarkers
- CE‑marked in‑vitro diagnostic software that meets regulatory requirements for clinical use
- Integration pathway through medical labs and hospital networks for easy ordering and result delivery
- Comprehensive reporting covering microbiome composition, functional potential, and disease‑associated signatures